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The neglected tropical disease (NTD) visceral leishmani-
asis (VL) has been targeted by the WHO for elimination
as a public health problem on the Indian subcontinent by
2017 or earlier. To date there is a surprising scarcity of
mathematical models capable of capturing VL disease
dynamics, which are widely considered central to plan-
ning and assessing the efficacy of interventions. The few
models that have been developed are examined,
highlighting the necessity for better data to parameter-
ise and fit these and future models. In particular, the
characterisation and infectiousness of the different dis-
ease stages will be crucial to elimination. Modelling can
then assist in establishing whether, when, and how the
WHO VL elimination targets can be met.
How mathematics can aid elimination of VL
VL (see Glossary) is a potentially fatal protozoan infection
transmitted by sandflies. Individuals with acute symp-
toms, referred to here as patients with kala-azar (KA),
show signs of fever, weight loss, splenomegaly, and anae-
mia; it is believed that almost all patients will die if left
untreated at this stage (http://www.who.int/mediacentre/
factsheets/fs375/en/). Following recovery from KA via drug
treatment, some patients go on to develop post-KA dermal
leishmaniasis (PKDL), a nonfatal stage of infection with
dermatological symptoms [1]. Worldwide, approximately
200 000–400 000 KA cases occur per year, the majority of
which occur on the Indian subcontinent (ISC): in India,
Bangladesh, and Nepal. VL on the ISC is anthroponotic
(i.e., there are no non-human primary hosts), it is trans-
mitted by just one vector species, Phlebotomus argentipes,
and the burden of disease is highly localised. As a conse-
quence, VL on the ISC is one of the NTDs that is targeted
by the WHO for elimination as a public health problem
(less than one new case of KA per 10 000 people per year)
by or before 2017 (http://apps.who.int/iris/handle/10665/
148778). In the rest of the world, VL is zoonotic (Box 1),
limiting the possibility of elimination, and therefore the
goal is 100% detection and treatment of all human cases by
2020 [2].
Within the ISC, the most affected area is the Bihar
district in northern India, where VL disproportionately
affects the poorest [3,4]. Despite falling numbers of cases
overall in the region [5], there remain hotspots of infection;
Bihar in particular accounts for approximately 80% of
reported cases on the ISC [6]. Currently, control pro-
grammes are based upon scaling up active case-detection
[7] and social mobilisation [5,8], which are both known to
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Glossary
Asymptomatic: patients who have active VL infection, are assumed to be
infective to sandflies (Box 3), but have no symptoms of KA.
Compartmental models: models in which the population is divided into
groups of people who progress through various stages of the disease,
represented as boxes or ‘compartments’ in the model. The classic example
of this is the susceptible–infected–recovered (SIR) basic epidemiological model
[53] in which everyone is considered to belong to one of those three stages.
Deterministic model: these models capture average behaviour of a population
and give the same outcome for a set of parameters in every simulation performed.
Dormant: those patients in this stage are between KA and PKDL; they still
harbour Leishmania parasites, but have no symptoms.
Exposed: patients who have acquired VL infection but are not yet infective to
sandflies.
(Fully) recovered: patients who have previously had VL infection (of any kind)
and are now parasite-free with acquired immunity.
Individual based model (IBM): a type of stochastic model where individual
humans are modelled separately under an overarching set of rules. These
allow for more complex simulations including differences between individual
people, their movements, and geographic setting.
Kala-azar (KA): literately translated as ‘black-fever’, this is the acute form of
visceral leishmaniasis. Patients display symptoms such as fever, weight loss,
swelling of the spleen or liver, and anaemia.
Non-symptomatic: all patients with VL infection but no symptoms: includes
exposed, asymptomatic, and dormant individuals (green boxes in Figure 1).
Post-kala-azar dermal leishmaniasis (PKDL): following KA, some individuals
(5–10%) develop PKDL, which is characterised by a nodular or papular skin
rash. It is non life-threatening.
Stochastic models: these allow for chance events as numbers of cases of
disease become small (in contrast to deterministic models). Simulated disease
dynamics vary every time; this allows the probability of events such as
elimination or re-occurrence to be found.
Visceral leishmaniasis (VL): general term for the disease caused by
Leishmania donovani (on the ISC) and L. infantum elsewhere. A VL patient
refers to all individuals harbouring the parasite, including those with and
without symptoms.
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be beneficial in reducing VL. Another essential part of
intervention programmes is vector control, usually
through indoor residual spraying (IRS) [9]; however, it is
not clear whether additional control measures are neces-
sary.
To ensure the success of the interventions in reaching
the WHO goals, it is vital to be able to examine critically
and quantitatively the outcome of different interventions
and to make quantitative assessments which will help in
the fight against this disease, particularly in the context of
limited resources and over a relatively short timescale.
Mathematical modelling provides tools to help evaluate
interventions to indicate both the intensity and timescale
over which an intervention might have to be carried out.
Modelling can also inform how long surveillance should be
in operation before elimination can be confirmed and how
elimination might be sustained. Therefore, it is important
to understand the limitations of existing models of VL on
the ISC, and how better data can improve the models and
generate results that are more directly useful for policy.
Insights from mathematical modelling studies are sum-
marised here through a literature review, and the differ-
ences in results or limitations are explained such that
lessons can be learnt for future models and current knowl-
edge gaps are identified.
Current state of mathematical modelling of VL
A thorough literature review was conducted to find all
mathematical transmission models of VL (further details
are given in the supplementary material online). Twenty-
four papers addressing relevant modelling of VL are sum-
marised in Table 1. Of these, only seven focused on the ISC;
the remainder mostly addressed transmission between
dogs in Brazil or France. These zoonotic papers were
included because of the cross-applicable insights that they
give (Box 1). Many of the articles were by the same authors
and thus there is a distinct overlap between many models.
For example, three of the most recent VL modelling papers
on the ISC were based on the same model [10–12]. The
models were rarely validated against recent data, with the
exception on the ISC being the papers by Stauch et al. [10–
12] and, to some extent, Mubayi et al. [13].
The models used a range of different assumptions re-
garding disease progression in humans, the intensity of
transmission, and the role of sandflies (discussed below).
Only two studies explicitly considered spatial aspects of
transmission [14,15].
The authors modelled a range of potential control strat-
egies to simulate the possible effects of intervention strat-
egies. On the ISC, treatment was modelled explicitly in all
but one paper (which is based on historical trends [16])
because this is the current course of action upon a diagno-
sis of VL. Two papers (by the same group [10,11]) explored
the impact of vector control on disease prevalence, and one
article computed the cost-effectiveness of a vaccine, should
one be developed [17].
Natural history of infection
An important difference between the models is the varying
assumptions about how the disease progresses, including
the probability of symptoms, the time between infection
and symptoms, and the dynamics post-treatment. The
limited knowledge about this process, also known as the
natural history of the infection, will affect the interpreta-
tion of model results and, therefore, they are discussed in
some detail here. There exists a general understanding of
the clinical progression of VL, but few datasets can assist in
quantifying the rates of progression or the probability of
different events. In general, following infection, most indi-
viduals remain non-symptomatic [18] whereas a few de-
velop KA. Those with KA have a high mortality rate in the
absence of treatment, often quoted in the literature to be
up to 100% within 2 years [2]. Relapses of KA sometimes
occur following treatment and this can be triggered by HIV
coinfection [19,20]. After successful treatment, patients
with KA recover, but this can be followed by the onset of
PKDL, possibly preceded by a period of dormancy of the
intracellular parasite. Unlike KA, PKDL is characterised
by a nodular or papular skin rash, has no associated
mortality and symptoms are dermatological. The occur-
rence of PKDL varies geographically: 5–10% of cases on
Box 1. What can we learn from VL in other regions?
The global picture: there are two types of parasite which cause VL:
Leishmania donovani and L. infantum. L. donovani is transmitted on
the ISC and East Africa and is the focus of this review. L. infantum is
responsible for most other VL infection, although some countries
have had outbreaks of disease due to both species [54]. The ISC has
the highest number of VL cases (58% of cases in 2012), followed by
East Africa (29%) and Brazil (8%) (http://www.who.int/research/en/).
(i) Zoonotic transmission
Transmission of VL that affects animals is largely associated
with L. infantum and is called zoonotic (ZVL). L donovani has
been found in animals in East Africa; however, it is considered
to have no animal reservoir on the ISC [55,56]. In Brazil, high
levels of infection occur in dog populations (canine or CVL), and
transmission between these populations and sandflies is
thought to drive VL transmission to humans.
(ii) Targeting the animal reservoir
Where there is ZVL, the animal reservoir provides important
opportunities for intervention, many of which have been
modelled (see Table 1 in main text). The control measures
used are largely inappropriate for consideration in the human
population and include strategies such as insecticidal dog
collars and culling, which reduce the force of infection towards
humans. Despite the crucial differences between these two
types of disease, lessons can be learnt (below), which can help
in the future modelling of VL on the ISC.
(iii) Parasite burden and transmission
Interestingly, as in humans, many PCR-positive dogs are also
asymptomatic, and this has been reflected in models of CVL
[57–59]. Different methods were used to compartmentalise the
dog population; either from clinical signs (i.e., symptomatic/
asymptomatic) or by infectivity of dogs to sandflies (i.e., ever-
infectious/never-infectious). Clinical status has been suggested
as a proxy for infectivity, as it has in humans, with one study
indicating that non-symptomatic infected dogs were around
threefold less infectious to sandflies than infected dogs with
multiple clinical signs of VL infection [58]. However, an
individual dog’s parasite burden also appears to be highly
correlated with relative infectivity, even if asymptomatic [58,60],
and this may be a better quantitative marker for infectiousness
in future models.
(iv) Diagnostics
Modelling of CVL in Brazil [59] indicates that high-specificity
diagnostics are crucial to correctly identify infectious indivi-
duals and intervene to reduce transmission. This provides a
modelling framework which could be adapted to explore the
issues of sensitivity/specificity of human diagnostics on the ISC.
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Table 1. Summary of VL modelling papers
Refs
Anthroponotic studies Zoonotic studies
[16] [61] [13] [62] [10]a [17] [12]a [11]a [63] [57] [40] [64] [65] [41] [58] [66] [67] [42] [28]b [29]b [14] [15]b [68] [59]
Model structure
Deterministic Uc U U U U U U U U U U U U U U U U U U U
Host-only U U U U U U U U U U U
Assumption
Asymptomatic humans U U U U
PKDL U U U U U U U
Humans U U U U U U U U y y y U U U U
Asymptomatic dogs U U U
Spatial aspects U U
Seasonality U U U U
Intervention
Human treatment U U U U U U U U U U
Human vaccination U U U
Vector control U U U U U
Dog culling U U U U U
Dog collar U U
Dog treatment U * U
Dog vaccination U U
Region India Sudan India ISC ISC India India ISC France   Brazil/
Malta
- Brazil Brazil Brazil Brazil Morocco Sudan  France  Brazil Brazil
aDenotes studies by Stauch et al. that use the same basic model.
bDenotes studies by ELmojtaba et al. that use the same basic model.
cU, included in model; y, dead-end hosts; *, implicitly included in other terms; , unclear or unknown region.
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ISC [1] and in up to 60% of cases in East Africa [21]. Ap-
proximately 10% of PKDL cases occur in individuals with
no history of KA, and occasionally it occurs concurrently
with KA [22,23].
The gold standard diagnostic for KA is parasitological
diagnosis of splenic aspirates, bone marrow, and lymph
node samples, with decreasing sensitivity, respectively.
Recently, rapid serological diagnostic tests [24,25] mainly
based on the rK39 antigen have been developed and are
implemented as primary diagnostic tools on ISC because of
their high sensitivity when combined with clinical symp-
toms. The direct agglutination test (DAT) is an alternative
serological test that has been proposed as an assay to
detect asymptomatic humans. Recently, it was suggested
that humans that are highly reactive to DAT have a
greater propensity to progress to symptomatic KA than
those with lower responses [6]. The leishmanin skin test
(LST) also measures serological response to infection and is
seen as a marker of exposure to infection, which is impor-
tant for understanding transmission but is not used in
clinical practice. Currently, it is unclear whether detection
of asymptomatic patients can be performed by measuring
the serological response to infection alone. Therefore, mo-
lecular tests, mainly PCR, based on the detection of para-
sitic DNA might be an alternative tool to detect humans
who are actively infected rather than only exposed to
disease [26]. It is important that the VL research commu-
nity focuses on the use of diagnostic tools for the detection
of asymptomatic cases such that clarity is reached on a
possible algorithm to detect infectious patients who are not
showing symptoms.
Modelling the natural history of infection
Most VL models are ‘compartmental’ models, which means
that hosts pass through various ‘stages’ of the disease at
different rates. A model can be constructed in which the
assumptions are closely tied to current understanding of
the biology. For example, the natural history outlined
above can be represented by a flow diagram (Figure 1)
with the model tracking the number of individuals in each
disease stage; the different rates of moving between stages,
such as the average time between KA and PKDL, are
defined either directly from knowledge of the disease or
by fitting the model to data.
Models of VL do not include all of the known complexity
of VL biology, mainly because of a lack of data to define the
stages, quantify the rates of progression between stages,
and chart the time-evolving distribution of the infected
population between stages. Basic models including key
aspects of VL transmission, guided by available data
and a particular policy or research question, can yield
invaluable insights.
For the ISC, the simplest model structure was the
susceptible–infected–recovered (SIR) progression as-
sumed by Dye and Wolpert [16] (Figure S1 in the supple-
mentary material online). This model was used to explain
the historical disease dynamics of VL in India between
1875 and 1950. Although the model is unsophisticated and
omits much of the currently known biological process of VL
infection, it was effectively fitted to longitudinal incidence
data, and the intrinsic processes were able to account for
the timings of the long interepidemic periods that are
characteristic of VL. A slightly more complex model was
that of Mubayi et al. which included a more realistic
latency period distribution, but did not include PKDL [13].
The probability and timing of PKDL following KA are
key assumptions for interpreting surveillance data and in
using models to make projections. The occurrence of PKDL
is thought to be governed by several factors, including the
choice of drugs and adherence to treatment [27]. Some
modellers (ELmojtaba et al. [15,28,29], Stauch et al. [10–
12], and Lee et al. [17]) incorporated the potential progres-
sion to PKDL infection following KA in humans via the
addition of another infective stage (Figure S2). This
enables one not only to observe the effect of different
treatment rates upon the two different types of disease
Humans Suscepble Exposed
KA
Asymptomac
Dormant PKDL
Fully
recovered
Sandﬂies Suscepble Infecous
Potenall y infecve
TRENDS in Parasitology 
Figure 1. Compartmental diagram showing possible visceral leishmaniasis (VL) progression paths. Differently coloured boxes denote humans at various stages of VL
infection: blue for no current infection, green for non-symptomatic but infected humans, and red for symptomatic individuals. Yellow boxes represent sandflies with and
without infection. The orange box indicates all human stages that are infected and that might be infective to sandflies (with likely varying intensities). Broken lines indicate
the direction of transmission between humans and sandflies, whereas unbroken lines show possible progression paths through different disease stages. Abbreviations: KA,
kala-azar; PKDL, post-KA dermal leishmaniasis.
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but also to examine how treatments that reduce the prob-
ability of developing PKDL might affect infection dynamics
and prevalence.
Inclusion of a dormancy period between KA and the
onset of possible PKDL (Figure 1) was used by two groups
(Stauch et al. [10–12] and Lee et al. [17]) to reflect the
longer duration of this period on the ISC [27].
Although the different stages of infection are loosely
based on current understanding of the clinical stages, the
precise definition of each stage in the model depends upon
the data used. For example, a KA case might be any KA
case, or it might be a diagnosed KA case in a particular
healthcare setting. Stauch et al. [10–12] particularly mod-
elled the KALANET trial [30]; this trial evaluated the
efficacy, acceptability, and cost-effectiveness of long-last-
ing insecticidal bed nets for the prevention of visceral
leishmaniasis through a community intervention trial in
the endemic Bihar focus (http://www.kalanet.info). Diag-
nosis of VL infection was made by three tests (PCR/DAT/
LST described in Table S1). The study revealed no signifi-
cant impact of bed nets [72], but it suggested that incidence
of asymptomatic Leishmania donovani infection in VL
high-endemic foci is ninefold more frequent than incident
VL disease [31].
Stauch et al., therefore, were able to partition the dif-
ferent stages of infection by their diagnostic status under
the three tests, in addition to symptoms, and treatment.
Although this method of compartmentalisation is only
subtly different from that general framework described
above, the stratification by different diagnostic tests struc-
tures the model slightly differently, with, for example, four
different ‘recovered’ stages by diagnostic status [10–12].
Given the availability of detailed data on diagnostic
outcomes, the Stauch et al. model included asymptomatic
individuals who tested positive with any of the three tests
but were unaware of their infection status in the absence of
diagnostic tests (Figure S3). The fact that asymptomatic
individuals can test positive leads to the question of their
infectivity to sandflies and of their role in the transmission
cycle (see below) and the specificity of the tests used.
An area of much debate in the VL research community is
the existence and action of immunity, which is currently
considered as a gap in our knowledge of VL [32,33]. The
models of Stauch et al. are the only ones to feature a return
to susceptibility after recovery from either KA or PKDL.
Under this model, immunity from reinfection lasts approx-
imately 307 days, which is short in comparison to the life-
long immunity assumed by other authors [10–12].
Different modellers have not only made different
assumptions about the natural history of VL but, impor-
tantly, also used different parameter ranges. The huge
variability in parameters and their values (Table S2) is
attributable not only to the underlying model structures
but also to the uncertainty in many factors in transmission
and progression, such as rates or probabilities, which are
either hard to measure or vary by region. Access to more
detailed datasets using modern diagnostics is essential to
revolutionise the study of VL transmission dynamics and
the utility of models to inform policy.
Transmission of VL
During the different stages of VL infection, individuals
harbour different levels of the parasite in their peripheral
blood and lymphatic systems [26]. Given that there is
apparently no sterile cure, once someone is infected they
can be infectious to sandflies throughout their lifetime,
including during the dormancy period before PKDL and
once PKDL develops (orange box in Figure 2). In particu-
lar, PKDL nodules are known to contain a detectable
parasitic load, implying potential significant infectivity
[34].
Both asymptomatic humans (Box 2) and those with
PKDL are unlikely to seek medical advice or treatment
[35] owing to the costs of treatment and the fact that
neither condition causes any physical limitation [36]; these
individuals are therefore behaviourally distinct from those
Humans Suscepble Exposed
KA
Asymptomac
Dormant PKDL
Fully
recovered
Sandﬂies Suscepble Infecous
TRENDS in Parasitology 
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Figure 2. Main ways to interrupt the transmission cycle of visceral leishmaniasis (VL) through interventions. Orange shows the effect of standard (first- or second-line)
treatment of symptomatic individuals. Pink shows the effect of vector controls. Grey shows the potential effect of bed nets. Purple shows the effect of a (potential) human
vaccine or other prophylactic intervention.
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with KA. Current active case detection relies on finding KA
symptoms before testing and, therefore, humans who are
asymptomatic are missed. The WHO has recommended
various regimens for PKDL based on geographical location,
but each has a long course and is associated with toxicities
[37]. In resource-poor settings, where VL is most prevalent,
these long parenteral regimens invariably lead to either
non-acceptance or poor compliance [38].
Infectivity to vectors
The infectivity of humans in different disease stages was
only identified in one model in which the authors explicitly
modelled asymptomatic humans with a decreased infectiv-
ity within the transmission cycle [10–12] (Box 3). Current-
ly, only two groups ([10–12] and [15,28,29]) have
incorporated PKDL into transmission models by assuming
comparable infectivity of KA- and PKDL-infected humans
because of lack of evidence to the contrary. The models with
an interim dormancy period before the onset of PKDL [10–
12] assumed that, during this time, the human host is not
infective to sandflies, whereas the other models [15,28,29]
assumed that individuals progress straight from KA to
PKDL, and are infective to sandflies throughout.
The cost–benefit analysis model [17] included both
asymptomatic humans and those with PKDL but, because
a constant force of infection was used, the role of these
patients towards onwards infection cannot be discerned.
These assumptions on the infectivity of asymptomatic
humans and patients with PKDL are crucial in determin-
ing the estimated efficacy of increased detection and treat-
ment of patients with KA. If there is a large asymptomatic
population, as indicated in the literature [31], then they
will probably lead to most of the onwards infection, even
with low infectivity, as might be the case with malaria
[39]. It could be argued that the decline in cases in Nepal
and Bangladesh under increased active case detection
suggests that the contribution from asymptomatics is
small, but this depends on the timescale and acquisition
of immunity as well as on the number of asymptomatic
humans and the impact of IRS in interrupting transmis-
sion. Although it is unlikely that direct estimates of asymp-
tomatic infectivity will be available soon, models could be
fitted to high-quality surveillance data, giving some
bounds to the contribution of different stages to transmis-
sion.
Vector biology
Sandflies are key in VL transmission, but little is known
about their life cycle, biting rates, and transmission prob-
abilities, all of which are crucial to increase understanding
of transmission dynamics. Even estimates of a parameter
as fundamental as sandfly life-expectancy have large con-
fidence intervals. Whereas models typically use an esti-
mate of 2 weeks, such estimates range from 2.4 to 16.7 days
(Table S3). Likewise, the seasonal fluctuations of sandfly
populations are only featured in some transmission models
of zoonotic VL [40–43], despite these fluctuations being one
of the easier parameters to measure. In future models
consideration should be made to the impact of sandfly
seasonality on the ISC and how this might affect vector
controls and their timing; this can be achieved by utilising
frameworks from zoonotic VL models as well as other
vector-borne disease models.
Effectiveness of interventions
There are several public health control measures that aim
to reduce the transmission of VL [44]. Some controls, such
as treatment of patients with KA, effectively speed up the
progression of patients through disease stages and mini-
mise the time that these individuals spend in the symp-
tomatic period, potentially reducing onwards infection to
sandflies. Other controls, such as insecticide spraying, aim
to reduce the vector population and its effectiveness
in transmitting infection. The four main parts of the
Box 3. Relative infectivity of asymptomatic humans
In the model by Stauch et al. [10–12], PCR- and/or DAT-seropositive
individuals, who are not symptomatic (termed ‘asymptomatics’ in
the papers), included both pre-KA patients and non-KA individuals.
These persons were estimated to be 40–80-fold less infective to
sandflies than their KA and PKDL counterparts, depending upon
their PCR/DAT status. This estimation is a result of model-fitting to
data from one study (KALANET) rather than direct biological
measurement.
Empirical evidence for relative infectivity of asymptomatics is
sparse [69,70], although one xenodiagnostic study [71] has enabled
the assessment of the relative infectivity of humans with different
parasitaemias (parasite burden) in Ethiopia. The data show similar
trends to those seen in Brazilian dogs (Box 1), and the correspond-
ing model analysis attributed between 53% and 79% of all sandfly
infections to the top 3.5% most-infected people, suggesting that
intervention strategies should focus on individuals with high
parasitaemia. Xenodiagnostics to determine relative infectivity on
the ISC have not yet been undertaken; however, the models of Miller
et al. and Courtney et al. [58,60,71] can be used as a basis for
incorporating relative infectiousness of different human disease
states into models before the outcomes of future human/sandfly
xenodiagnostic studies are known.
Box 2. What is an asymptomatic VL case?
The green boxes in Figure 1 in main text identify infected individuals
without symptoms. Identifying this group of non-symptomatic
humans in cross-sectional or longitudinal studies is difficult because
of contradictory diagnostic results [6]. For the purposes of
transmission modelling, the subsets of these (termed here as
exposed, asymptomatic, and dormant) are different because only
those within the orange box can contribute to onwards infection.
There is ambiguity in the term ‘asymptomatic’ as it is used in the
context of VL. It can include or exclude those humans with
subsymptomatic early infection, non-symptomatic early infection,
as well as post-treatment or recovery dormancy. From an epide-
miological perspective, the term is used for individuals who display
no outward symptoms of VL infection but do harbour parasites. For
the purposes of this review and to assist in future modelling studies,
the term ‘asymptomatic’ is used here to describe the subset of these
humans capable of contributing towards transmission. Non-symp-
tomatics are identified together with asymptomatics in some types
of data collection, but in terms of transmission models they are
entirely distinct or absent, with no role in transmission. This
distinction is made because of the difficulty in separating exposed,
uninfected, possibly seropositive, individuals from subpatent infec-
tions in cross-sectional studies because of conflicting diagnostic
results (see main text). The definition of these groups by particular
diagnostics is an area of ongoing research and debate, which future
xenodiagnostic studies will clarify; these studies involve exposing
vectors to blood containing various levels of parasites and then
establishing infection probabilities.
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transmission cycle that are affected by interventions (both
current and hypothetical) are highlighted in Figure 2. Each
of these interventions has been discussed within one or
more of the articles found by this review, and their model-
ling methods and results are discussed below.
Treatment of KA
Given the high mortality rate for untreated KA, most
patients are believed to seek care eventually, although
the time-delay before treatment can be long [8]. There
are a variety of treatments available for KA, but some
studies suggest that adherence, rather than treatment
type, is the key factor that might result in differing proba-
bilities of progression to PKDL or relapse to KA [45].
In the model analysis by ELmojtaba et al. [28], both
first-line treatment rate and effectiveness of preventing
PKDL are varied. The authors found that, with high
treatment rates alone, there was a reduction in KA cases,
but, because a proportion of these treatments produced a
PKDL case, infection rates were still high. Unsurprisingly,
increasing both treatment and effectiveness was more
efficacious at reducing transmission.
Stauch et al. [10–12] included three treatment types:
first-line treatment of KA, second-line treatment following
first-line treatment failure, and PKDL treatment. The
authors showed that high treatment rates reduced the
number of KA and PKDL cases. However, the intervention
had almost no impact upon the large asymptomatic popu-
lation and, consequently, transmission intensity was little
affected [10].
These two groups of papers suggest that treatment
alone will not be enough to truly halt the transmission
of VL, and that other interventions are needed when
aiming for elimination, echoing the opinion of others [5,46].
Vaccine
There is currently no human vaccine for VL; however,
advances are being made and models have been used to
study the benefits of potential candidates [32,47]. Lee et al.
[17] described the possible advantages of a VL vaccine
through a cost–benefit analysis. They found that even a
poorly effective vaccine (25% effective – a vaccine that fully
protects 25% of those immunised against infection, but
makes no difference to the remaining 75%) might be cost-
effective (for US$ 100 or less), whereas vaccines with
higher effectiveness might even be cost-saving. For Bihar,
India, in particular, this work indicated that a vaccine
would be beneficial because of the high prevalence of
genetic resistance to first-line treatments that has devel-
oped in this region. This model [17] used a constant (age-
dependent) force of infection that did not change in re-
sponse to vaccine use. Consequently, it is hard to deter-
mine what indirect effects the vaccine might have on
reducing disease prevalence.
ELmojtaba et al. [15] showed that vaccination rates
affected the transient dynamics through the rate of reduc-
tion of cases (in Sudan) but ultimately had little role in
long-term prevalences where new cases are continuously
imported. In particular, the authors noted that high levels
of vaccine efficacy would be needed to reduce the equilibri-
um prevalence of VL significantly.
These contrasting results highlight the importance of
understanding the underlying assumptions of the models
when interpreting their results, and that the potential
impact of a future vaccine is still uncertain.
Vector control
The main intervention for vector control is IRS, which is
linked to a reduction in sandfly life expectancy and to a
consequent reduction in sandfly populations [9]. Lowering
the total vector population size reduces the biting pressure
on each human by decreasing the ratio of vectors to hosts
(Figure 2). By reducing the sandfly life-expectancy, the
vector is less likely to survive long enough to bite twice –
once to acquire infection and again to infect a host. As the
vector death rate increases, vectors spend less time
infected.
Other interventions include reductions in sandfly breed-
ing sites, which also limits population sizes, and insecti-
cide-treated bed nets [44]. The use of bed nets decreases
the contact rate between vectors and humans and, conse-
quently, should lower transmission, not only to susceptible
individuals, but also from infected ones, including asymp-
tomatic humans and those with PKDL. Unfortunately, the
KALANET programme indicated that, despite a reduction
in sandfly density, bed nets were not effective at reducing
incidence in this setting and, thus, IRS remains the main
control strategy [48,49].
Given the limited data on sandfly behaviour (as men-
tioned above), model assumptions and outputs are vari-
able. Stauch et al. [10] examined the effect of changing the
three parameters corresponding to vector life-expectancy,
vector population size, and bite rate. Each of the param-
eters appeared to result in a quasi-linear change in preva-
lence and incidence of infection. Further work by Stauch
et al. [11] examined control of vector breeding sites and
killing vectors directly. These authors suggested that, to
break transmission, either the vector population must be
reduced by 79% through the destruction of breeding sites or
it must be reduced by 67% by killing adult flies, the latter
effectively decreasing the life-expectancy of the sandflies in
addition to suppressing their population size.
Concluding remarks
Modelling is a useful tool in informing public health control
programmes, but to date there have been relatively few VL
models developed. This is partly because of the status of VL
as an NTD with limited data availability. Modelling results
point towards IRS in particular as a highly promising strat-
egy to control transmission of VL. However, it is difficult to
determine the best way forward to achieve the goals of the
WHO given the current state of knowledge. The main weak-
ness of the current modelling literature is the lack of fitting
or validation against multiple timepoint data. The one model
parameterised by a modern dataset is only fitted to the cross-
sectional, rather than the dynamic data [10–12]. There is an
urgent need for more models of VL to be developed which can
aid public health policy by analysing surveillance data and
guide policy on areas where current strategies need to be
improved. PKDL cases continue to occur from historic VL
cases, cost-effective strategies to monitor these cases and
limit onward transmission are required.
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The current suite of models are also limited in terms of
the technical complexity and analyses which have been
performed, such as exploring asymptotic/PKDL infectivity,
sandfly seasonality, age-dependent exposure, and differ-
ences (both age and gender related) in treatment-seeking
behaviour. Currently no stochastic individual-based mod-
els (IBM) exist that capture the transmission dynamics of
VL. Stochastic models can simulate the probability of
elimination as well as the probability of (re)-occurrence
of outbreaks, both identified as crucial questions for VL on
the ISC. Another technical need is for IBMs that can
include more complexity including seasonality, migration
and location. IBMs for other NTDs have shown to be of
great value in aiding healthcare policy, such as estimating
the impact of doubling the frequency of mass drug admin-
istration to accelerate elimination of onchocerciasis [50]
and lymphatic filariasis [51], as well as combining various
preventive and therapeutic interventions to interrupt lep-
rosy transmission [52].
Surveillance data, together with prior experience of the
epidemiology of elimination, suggest that, although there
are geographical areas where the current programmes will
be successful, there will be those where additional inter-
ventions are required. If goals for the ISC, as well as long-
term suppression of transmission, are to be achieved, it is
essential that the transmission dynamics are understood
and that intervention programmes are designed to maxi-
mise the reduction in transmission and the long-term
sustainability of these goals. Availability of surveillance
and research data is necessary to inform future models for
them to be an effective tool to support the hugely impres-
sive efforts to control VL on the ISC. As new datasets
become available through the labours of experimental and
field researchers, there are now opportunities for existing
model refinement and novel model exploration to address
outstanding questions (Box 4). To meet the ambitious
targets of the WHO, it will be essential to maintain dia-
logue between modellers and programme managers, policy
makers, and other researchers working to combat this
disease.
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